糖尿病治療薬の世界市場：市場規模・シェア・動向、業界分析 (種類別・薬剤クラス別・投与経路別・流通チャネル別・地域別)、将来予測 (2025年～2034年)

Polaris Market Research社の最新調査によると、糖尿病治療薬の市場規模は2034年までに1,637億9,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

糖尿病治療薬市場の成長は、人口の高齢化、座りがちなライフスタイル、肥満率の増加などの要因による糖尿病、特に2型糖尿病の世界の有病率の上昇に起因しています。主な促進要因としては、薬剤製剤の進歩、GLP-1受容体作動薬やSGLT-2阻害薬などの新規治療薬のイントロダクション、心血管疾患や腎合併症などの併存疾患の管理に対する関心の高まりなどが挙げられます。糖尿病治療薬の市場開拓は、糖尿病の有病率が上昇している新興国市場や、併用療法や個別化医療の開発にビジネスチャンスが存在します。

市場に影響を与える主な動向としては、より良い疾病管理のためのデジタルヘルス技術の採用、バイオシミラーの使用増加、非侵襲的治療の重視などが挙げられます。全体として、効果的で利便性の高い糖尿病管理ソリューションに対する需要の高まりに対応するために医療システムが進化するにつれて、市場は拡大を続けると予想されます。

糖尿病治療薬市場：分析概要

種類別では、2型糖尿病が糖尿病治療薬市場の売上高で大きなシェアを占めており、肥満率の上昇と高齢化によって高い成長を遂げています。このセグメントは、インスリン療法とインスリン送達システムの進歩に支えられて成長を続けています。

投与経路別では経口投与セグメントが、特にメトホルミンやSGLT-2阻害剤などの薬剤において、その利便性と広く受け入れられていることから、糖尿病治療薬市場のシェアを独占しています。静脈内投与セグメントは、市場シェアは最も小さいもの、特にインスリンポンプの使用や病院での専門的な治療により、着実に成長しています。

薬剤クラス別では、特に1型糖尿病治療においてインスリン製剤が依然として優位を保っていますが、SGLT-2阻害薬は、特に2型糖尿病管理における心血管保護と腎保護におけるその他の特典に牽引され、最も急速に成長しています。

北米は、高い糖尿病罹患率と先進的な医療インフラに牽引され、最大の市場シェアを占めています。一方、アジア太平洋は、糖尿病患者の増加と医療アクセスの改善に後押しされ、最も急速に成長している地域です。

糖尿病治療薬市場の主要企業には、ノボ・ノルディスク、サノフィ、イーライリリー、メルク、ベーリンガー・インゲルハイムなどの大手製薬会社が含まれます。これらの企業は、インスリン治療薬、GLP-1受容体作動薬、SGLT-2阻害薬など、幅広い糖尿病治療薬の開発、製造、販売に積極的に取り組んでいます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 世界の糖尿病治療薬市場の洞察

• 市場スナップショット
• 糖尿病治療薬の市場力学
  • 促進要因と機会
    • GLP-1受容体作動薬の採用増加
    • 糖尿病の個別治療への移行
  • 抑制要因と課題
    • 糖尿病治療薬の高コスト
• PESTLE分析
• 糖尿病治療薬市場の動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界の糖尿病治療薬市場：種類別

• 主な分析結果
• イントロダクション
• 1型
• 2型

第6章 世界の糖尿病治療薬市場：投与経路別

• 主な分析結果
• イントロダクション
• 経口
• 静脈内

第7章 世界の糖尿病治療薬市場：薬剤クラス別

• 主な調査結果
• イントロダクション
• インスリン
• 感作剤
• SGLT-2阻害剤
• アルファグルコシダーゼ阻害剤

第8章 世界の糖尿病治療薬市場：エンドユーザー別

• 主な分析結果
• イントロダクション
• 病院・クリニック
• 外来クリニック

第9章 世界の糖尿病治療薬市場：地域別

• 主な分析結果
• イントロダクション
  • 糖尿病治療薬市場の評価：地域別 (2020～2034年)
• 北米
  • 北米：種類別 (2020～2034年)
  • 北米：投与経路別 (2020～2034年)
  • 北米：薬剤クラス別 (2020～2034年)
  • 北米：エンドユーザー別 (2020～2034年)
  • 米国
  • カナダ
• 欧州
  • 欧州：種類別 (2020～2034年)
  • 欧州：投与経路別 (2020～2034年)
  • 欧州：薬剤クラス別 (2020～2034年)
  • 欧州：エンドユーザー別 (2020～2034年)
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
  • その他欧州
• アジア太平洋
  • アジア太平洋：種類別 (2020～2034年)
  • アジア太平洋：投与経路別 (2020～2034年)
  • アジア太平洋：薬剤クラス別 (2020～2034年)
  • アジア太平洋：エンドユーザー別 (2020～2034年)
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ
  • 中東・アフリカ：種類別 (2020～2034年)
  • 中東・アフリカ：投与経路別 (2020～2034年)
  • 中東・アフリカ：薬剤クラス別 (2020～2034年)
  • 中東・アフリカ：エンドユーザー別 (2020～2034年)
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東・アフリカ
• ラテンアメリカ
  • ラテンアメリカ：種類別 (2020～2034年)
  • ラテンアメリカ：投与経路別 (2020～2034年)
  • ラテンアメリカ：薬剤クラス別 (2020～2034年)
  • ラテンアメリカ：エンドユーザー別 (2020～2034年)
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ

第10章 競合情勢

• 事業拡大・企業買収の分析
  • 事業拡大
  • 企業買収
• 提携/協業/合意/公開

第11章 企業プロファイル

• Novo Nordisk
• Sanofi
• Eli Lilly
• Merck
• Boehringer Ingelheim
• AstraZeneca
• Johnson & Johnson
• Novartis
• Bayer
• GlaxoSmithKline

List of Tables:

• Table 1 Global Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 2 Global Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 3 Global Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 4 Global Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 5 North America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 6 North America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 7 North America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 8 North America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 9 U.S.: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 10 U.S.: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 11 U.S.: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 12 U.S.: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 13 Canada: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 14 Canada: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 15 Canada: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 16 Canada: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 17 Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 18 Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 19 Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 20 Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 21 UK: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 22 UK: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 23 UK: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 24 UK: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 25 France: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 26 France: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 27 France: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 28 France: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 29 Germany: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 30 Germany: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 31 Germany: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 32 Germany: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 33 Italy: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 34 Italy: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 35 Italy: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 36 Italy: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 37 Spain: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 38 Spain: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 39 Spain: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 40 Spain: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 41 Netherlands: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 42 Netherlands: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 43 Netherlands: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 44 Netherlands: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 45 Russia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 46 Russia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 47 Russia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 48 Russia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 49 Rest of Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 50 Rest of Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 51 Rest of Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 52 Rest of Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 53 Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 54 Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 55 Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 56 Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 57 China: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 58 China: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 59 China: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 60 China: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 61 India: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 62 India: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 63 India: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 64 India: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 65 Malaysia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 66 Malaysia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 67 Malaysia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 68 Malaysia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 69 Japan: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 70 Japan: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 71 Japan: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 72 Japan: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 73 Indonesia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 74 Indonesia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 75 Indonesia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 76 Indonesia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 77 South Korea: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 78 South Korea: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 79 South Korea: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 80 South Korea: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 81 Australia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 82 Australia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 83 Australia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 84 Australia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 85 Rest of Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 86 Rest of Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 87 Rest of Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 88 Rest of Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 89 Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 90 Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 91 Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 92 Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 93 Saudi Arabia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 94 Saudi Arabia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 95 Saudi Arabia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 96 Saudi Arabia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 97 UAE: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 98 UAE: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 99 UAE: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 100 UAE: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 101 Israel: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 102 Israel: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 103 Israel: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 104 Israel: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 105 South Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 106 South Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 107 South Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 108 South Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 109 Rest of Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 110 Rest of Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 111 Rest of Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 112 Rest of Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 113 Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 114 Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 115 Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 116 Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 117 Mexico: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 118 Mexico: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 119 Mexico: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 120 Mexico: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 121 Brazil: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 122 Brazil: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 123 Brazil: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 124 Brazil: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 125 Argentina: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 126 Argentina: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 127 Argentina: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 128 Argentina: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• Table 129 Rest of Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 130 Rest of Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• Table 131 Rest of Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• Table 132 Rest of Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)

List of Figures:

• Figure 1. Global Diabetes Drugs Market, 2020-2034 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Price
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Type
• Figure 7. Global Diabetes Drugs Market, by Type, 2024 & 2034 (USD Billion)
• Figure 8. Market by Administration
• Figure 9. Global Diabetes Drugs Market, by Administration, 2024 & 2034 (USD Billion)
• Figure 10. Market by Drug Class
• Figure 11. Global Diabetes Drugs Market, by Drug Class, 2024 & 2034 (USD Billion)
• Figure 12. Market by End Users
• Figure 13. Global Diabetes Drugs Market, by End Users, 2024 & 2034 (USD Billion)

The diabetes drug market size is expected to reach USD 163.79 billion by 2034, according to a new study by Polaris Market Research. The report "Diabetes Drug Market Size, Share, Trends, Industry Analysis Report: By Type (Type 1 and Type 2), Drug Class, Route of Administration, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The diabetes drug market growth is attributed to the rising global prevalence of diabetes, particularly type 2 diabetes, due to factors such as aging populations, sedentary lifestyles, and increasing obesity rates. Key drivers include advancements in drug formulations, the introduction of new therapies such as GLP-1 receptor agonists and SGLT-2 inhibitors, and an increasing focus on managing comorbidities such as cardiovascular disease and renal complications. Diabetes drug market opportunities exist in emerging markets where the prevalence of diabetes is rising, as well as in the development of combination therapies and personalized medicine.

Key trends influencing the market include the adoption of digital health technologies for better disease management, the rise in use of biosimilars, and an emphasis on noninvasive treatments. Overall, the market is expected to continue expanding as healthcare systems evolve to address the growing demand for effective and convenient diabetes management solutions.

Diabetes Drug Market Report Highlights

Based on type, the type-2 diabetes holds a larger share of the diabetes drug market revenue and is experiencing a higher growth, driven by rising obesity rates and an aging population. The segment continues to grow, supported by advancements in insulin therapies and insulin delivery systems.

The oral administration segment, based on route of administration, dominates the diabetes drug market share due to its convenience and wide acceptance, particularly with drugs such as metformin and SGLT-2 inhibitors. The intravenous segment, while holding the smallest market share, is growing steadily, particularly due to the use of insulin pumps and specialized treatments in hospitals.

Based on drug class, the insulin segment remains the dominant segment, especially in type-1 diabetes treatment, but SGLT-2 inhibitors is the fastest-growing segment, driven by their additional benefits in cardiovascular and renal protection, especially in type-2 diabetes management.

North America holds the largest market share, driven by high diabetes prevalence and advanced healthcare infrastructure, whereas Asia Pacific is the fastest-growing region, fueled by rising diabetes cases and improving healthcare access.

A few key players in the diabetes drug market include major pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies are actively involved in the development, production, and distribution of a wide range of diabetes treatments, including insulin therapies, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Polaris Market Research has segmented the diabetes drug market report on the basis of type, route of administration, drug class, distribution channel, and region:

By Type Outlook (Revenue - USD Billion, 2020-2034)

• Type-1
• Type-2

By Administration Outlook (Revenue - USD Billion, 2020-2034)

• Oral
• Intravenous
• Subcutaneous

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

• Insulin
• Sensitizers
• SGLT-2 Inhibitors
• Alpha-Glucosidase Inhibitors
• Others
• By Distribution Channel (Revenue - USD Billion, 2020-2034)
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Diabetes Drugs Market Insights

• 4.1. Diabetes Drugs Market - Market Snapshot
• 4.2. Diabetes Drugs Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Adoption of GLP-1 Receptor Agonists
    • 4.2.1.2. Shift Towards Personalized Diabetes Treatments
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Cost of Diabetes Medications
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Diabetes Drugs Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Diabetes Drugs Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
• 5.3. Type-1
  • 5.3.1. Global Diabetes Drugs Market, by Type-1, by Region, 2020-2034 (USD Billion)
• 5.4. Type-2
  • 5.4.1. Global Diabetes Drugs Market, by Type-2, by Region, 2020-2034 (USD Billion)

6. Global Diabetes Drugs Market, by Administration

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
• 6.3. Oral
  • 6.3.1. Global Diabetes Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
• 6.4. Intravenous
  • 6.4.1. Global Diabetes Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)

7. Global Diabetes Drugs Market, by Drug Class

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
• 7.3. Insulin
  • 7.3.1. Global Diabetes Drugs Market, by Insulin, by Region, 2020-2034 (USD Billion)
• 7.4. Sensitizers
  • 7.4.1. Global Diabetes Drugs Market, by Sensitizers, by Region, 2020-2034 (USD Billion)
• 7.5. SGLT-2 Inhibitors
  • 7.5.1. Global Diabetes Drugs Market, by SGLT-2 Inhibitors, by Region, 2020-2034 (USD Billion)
• 7.6. Alpha-Glucosidase Inhibitors
  • 7.6.1. Global Diabetes Drugs Market, by Alpha-Glucosidase Inhibitors, by Region, 2020-2034 (USD Billion)

8. Global Diabetes Drugs Market, by End Users

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• 8.3. Hospital & Clinics
  • 8.3.1. Global Diabetes Drugs Market, by Hospital & Clinics, by Region, 2020-2034 (USD Billion)
• 8.4. Ambulatory Clinics
  • 8.4.1. Global Diabetes Drugs Market, by Ambulatory Clinics, by Region, 2020-2034 (USD Billion)

9. Global Diabetes Drugs Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Diabetes Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
• 9.3. Diabetes Drugs Market - North America
  • 9.3.1. North America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.3.2. North America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 9.3.3. North America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.3.4. North America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.3.5. Diabetes Drugs Market - US
    • 9.3.5.1. US: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.3.5.2. US: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.3.5.3. US: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.3.5.4. US: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.3.6. Diabetes Drugs Market - Canada
    • 9.3.6.1. Canada: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.3.6.2. Canada: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.3.6.3. Canada: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.3.6.4. Canada: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• 9.4. Diabetes Drugs Market - Europe
  • 9.4.1. Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.4.2. Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 9.4.3. Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.4.4. Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.5. Diabetes Drugs Market - UK
    • 9.4.5.1. UK: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.5.2. UK: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.5.3. UK: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.5.4. UK: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.6. Diabetes Drugs Market - France
    • 9.4.6.1. France: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.6.2. France: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.6.3. France: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.6.4. France: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.7. Diabetes Drugs Market - Germany
    • 9.4.7.1. Germany: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.7.2. Germany: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.7.3. Germany: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.7.4. Germany: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.8. Diabetes Drugs Market - Italy
    • 9.4.8.1. Italy: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.8.2. Italy: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.8.3. Italy: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.8.4. Italy: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.9. Diabetes Drugs Market - Spain
    • 9.4.9.1. Spain: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.9.2. Spain: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.9.3. Spain: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.9.4. Spain: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.10. Diabetes Drugs Market - Netherlands
    • 9.4.10.1. Netherlands: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.10.2. Netherlands: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.10.3. Netherlands: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.10.4. Netherlands: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.11. Diabetes Drugs Market - Russia
    • 9.4.11.1. Russia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.11.2. Russia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.11.3. Russia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.11.4. Russia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4.12. Diabetes Drugs Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.12.2. Rest of Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.12.3. Rest of Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.12.4. Rest of Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• 9.5. Diabetes Drugs Market - Asia Pacific
  • 9.5.1. Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.5.2. Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 9.5.3. Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.5.4. Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.5. Diabetes Drugs Market - China
    • 9.5.5.1. China: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.5.2. China: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.5.3. China: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.5.4. China: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.6. Diabetes Drugs Market - India
    • 9.5.6.1. India: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.6.2. India: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.6.3. India: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.6.4. India: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.7. Diabetes Drugs Market - Malaysia
    • 9.5.7.1. Malaysia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.7.2. Malaysia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.7.3. Malaysia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.7.4. Malaysia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.8. Diabetes Drugs Market - Japan
    • 9.5.8.1. Japan: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.8.2. Japan: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.8.3. Japan: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.8.4. Japan: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.9. Diabetes Drugs Market - Indonesia
    • 9.5.9.1. Indonesia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.9.2. Indonesia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.9.3. Indonesia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.9.4. Indonesia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.10. Diabetes Drugs Market - South Korea
    • 9.5.10.1. South Korea: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.10.2. South Korea: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.10.3. South Korea: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.10.4. South Korea: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.11. Diabetes Drugs Market - Australia
    • 9.5.11.1. Australia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.11.2. Australia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.11.3. Australia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.11.4. Australia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5.12. Diabetes Drugs Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.12.2. Rest of Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.12.3. Rest of Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.12.4. Rest of Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• 9.6. Diabetes Drugs Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.6.2. Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 9.6.3. Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.6.4. Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6.5. Diabetes Drugs Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6.6. Diabetes Drugs Market - UAE
    • 9.6.6.1. UAE: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.6.2. UAE: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.6.3. UAE: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.6.4. UAE: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6.7. Diabetes Drugs Market - Israel
    • 9.6.7.1. Israel: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.7.2. Israel: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.7.3. Israel: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.7.4. Israel: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6.8. Diabetes Drugs Market - South Africa
    • 9.6.8.1. South Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.8.2. South Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.8.3. South Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.8.4. South Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6.9. Diabetes Drugs Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.9.2. Rest of Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.9.3. Rest of Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.9.4. Rest of Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
• 9.7. Diabetes Drugs Market - Latin America
  • 9.7.1. Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 9.7.2. Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 9.7.3. Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 9.7.4. Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.7.5. Diabetes Drugs Market - Mexico
    • 9.7.5.1. Mexico: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.5.2. Mexico: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.7.5.3. Mexico: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.7.5.4. Mexico: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.7.6. Diabetes Drugs Market - Brazil
    • 9.7.6.1. Brazil: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.6.2. Brazil: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.7.6.3. Brazil: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.7.6.4. Brazil: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.7.7. Diabetes Drugs Market - Argentina
    • 9.7.7.1. Argentina: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.7.2. Argentina: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.7.7.3. Argentina: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.7.7.4. Argentina: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.7.8. Diabetes Drugs Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.8.2. Rest of Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.7.8.3. Rest of Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.7.8.4. Rest of Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Novo Nordisk
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Sanofi
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Eli Lilly
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Merck
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Boehringer Ingelheim
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. AstraZeneca
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Johnson & Johnson
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Novartis
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Bayer
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. GlaxoSmithKline
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development